ArticleFrontiers in oncology2026
Long-term management of orbital Rosai-Dorfman disease with re-irradiation for locoregional recurrence: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans histiocytic disorder with occasional extranodal involvement. Orbital disease can mimic neoplastic or inflammatory conditions, leading to diagnostic and therapeutic challenges. Standardized management strategies remain undefined. Aim: To describe the diagnostic complexity and therapeutic role of radiation therapy, including re-irradiation, in orbital RDD. Case presentation: A 58-year-old male presented with nasal obstruction, later progressing to orbital involvement. Histopathology confirmed RDD (S100+, CD68+, CD1a-). Initial corticosteroid therapy provided partial relief. Image-guided radiotherapy (36 Gy in 20 fractions) achieved complete remission for five years. On recurrence with proptosis and compressive optic neuropathy, re-irradiation (24 Gy in 12 fractions) was delivered after careful review of prior dose constraints. The patient demonstrated improved visual acuity (6/60 to 6/36), stable MRI findings, and no late radiation toxicity at two-year follow-up. Conclusion: This case highlights the feasibility and efficacy of radiation therapy, including re-irradiation, in orbital RDD when medical management fails. Re-irradiation achieved durable local control, preserved visual function, and adds to the limited evidence supporting its role in recurrent disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.